-
-
-
-
-
-
-
Guggenheim on AnaptysBio (ANAB) Spinoff: 'Additional potential upside may be derived from imsidolimab in generalized pustular psoriasis'
-
-
-
-
-
-
-
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
-
-
-
-
-
-
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
-
-
-
-
-
-
-
AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update
-
-
-
-
-
-
-
AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates
-
1,207,350 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

